Andrew Brooks

Brooks died of a heart attack on January 23, 2021. New Jersey Governor Phil Murphy lauded him as an "unsung hero".

Brooks was also both COO and director of technology of RUCDR Infinite Biologics. At RUCDR, he developed a saliva-spit test for COVID-19 as an alternative to naso- or oropharyngeal swab tests which both increased speed of results and minimized the need for medical professionals to be involved in the testing process. He used the capabilities built up to perform genetic tests through saliva and adapted the same techniques to extract the necessary RNA from the virus. The test received emergency use authorization from the FDA in April 2020, making it the first at-home test to be approved by federal authorities. In addition to designing the saliva test he commercialized the test and scaled production operations to meet the rollout demands. More than 4 million people have used the test.

In 2009, Brooks began working at the Rutgers University Cell and DNA Repository (RUCDR), a university-company for data management and research analysis. He eventually became CEO of the company and it became a private entity, now called Sampled, in 2018. He was also the chief science officer for Spectrum Solutions. He was a member of the New Jersey Economic Advisory Council, and the director of the Bionomics Research and Technology Center (BRTC) at the Environmental and Occupational Health Science Institute of the University of Medicine and Dentistry of New Jersey.

Andrew Ira Brooks (February 10, 1969 – January 23, 2021) was an American immunologist, academic, and businessman. He was an associate research professor at Rutgers University and the developer of the first FDA-approved rapid saliva test for COVID-19 diagnosis.

Brooks was born in Bronxville, New York, on February 10, 1969, to Phyllis (née Heitner) and Perry H. Brooks. His mother was a school teacher while his father was a diamond setter. He was raised in Old Bridge Township, New Jersey and later attended Cornell University, majoring in animal sciences with the intention of becoming a veterinarian. He switched his academic focus after a summer internship at Memorial Sloan Kettering and in 2000 received a PhD from University of Rochester in neuroscience.